Profile data is unavailable for this security.
About the company
Sonoma Pharmaceuticals, Inc. is engaged in developing and producing stabilized hypochlorous acid (HOCl), products for a range of applications, including wound care, animal health care, eye care, oral care and dermatological conditions. The Company's product offerings include Regenacyn Advanced Scar Gel, Regenacyn Plus Scar Gel, Rejuvacyn Advanced Skin Repair Cooling Mist, Pediacyn Skin Care, Microcyn, Ocucyn Eyelid and Eyelash Cleanser, Microdacyn60 Oral Care, Podiacyn Advanced Everyday Foot Care, and MicrocynAH. Regenacyn Advanced Scar Gel helps to improve the overall appearance of scars while reducing pain, itch, redness, and inflammation. Regenacyn Plus is a prescription-strength scar gel which is available as an office dispense product through dermatology practices and medical spas. Pediacyn is a pediatric dermatology and wound care product for over-the-counter use. MicrocynAH is a HOCl-based topical product that cleans, debrides and treats a range of animal wounds and infections.
- Revenue in USD (TTM)12.31m
- Net income in USD-5.08m
- Incorporated2006
- Employees9.00
- LocationSonoma Pharmaceuticals Inc5445 CONESTOGA COURT, SUITE 150BOULDER 80301United StatesUSA
- Phone+1 (617) 243-0050
- Fax+1 (707) 283-0551
- Websitehttps://sonomapharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zyversa Therapeutics Inc | 0.00 | -106.25m | 3.41m | 7.00 | -- | 0.1642 | -- | -- | -1,922.89 | -1,922.89 | 0.00 | 27.33 | 0.00 | -- | -- | 0.00 | -139.81 | -- | -160.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -340.15 | -- | -- | -- |
| Onconetix Inc | 58.47k | -37.41m | 3.48m | 12.00 | -- | -- | -- | 59.57 | -2.09 | -2.09 | 0.0034 | 2.63 | 0.001 | -- | 0.6301 | 4,872.50 | -65.73 | -- | -87.29 | -- | -1,927.76 | -- | -63,981.00 | -- | 0.3185 | -19.88 | 0.1292 | -- | -- | -- | -176.78 | -- | -- | -- |
| Altamira Therapeutics Ltd | 0.00 | -8.00m | 3.49m | 10.00 | -- | 0.3244 | -- | -- | -16.28 | -8.67 | 0.00 | 4.81 | 0.00 | 34.05 | 32.30 | 0.00 | -103.88 | -73.80 | -6,364.67 | -123.19 | -87.90 | -- | -- | -- | 1.38 | -4.37 | 0.0152 | -- | -- | -- | 61.02 | -- | -- | -- |
| Bon Natural Life Ltd | 29.52m | 4.60m | 3.53m | 96.00 | 0.5070 | 0.0837 | 0.6403 | 0.1195 | 4.99 | 4.99 | 32.10 | 30.23 | 0.7045 | 15.27 | 5.19 | 307,524.60 | 10.86 | 14.04 | 13.69 | 20.68 | 29.94 | 30.00 | 15.42 | 17.62 | 2.41 | 30.54 | 0.0955 | 0.00 | -1.29 | 22.32 | -26.32 | 83.09 | -6.70 | -- |
| Bio Path Holdings Inc | 0.00 | -13.96m | 3.54m | 10.00 | -- | -- | -- | -- | -27.39 | -27.39 | 0.00 | -3.48 | 0.00 | -- | -- | 0.00 | -216.97 | -70.80 | -390.65 | -76.87 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -15.94 | -- | -- | -- |
| Phio Pharmaceuticals Corp | 0.00 | -9.38m | 3.61m | 8.00 | -- | 0.6448 | -- | -- | -3.71 | -3.71 | 0.00 | 1.22 | 0.00 | -- | -- | 0.00 | -113.26 | -71.92 | -145.23 | -84.15 | -- | -- | -- | -253,785.70 | -- | -- | 0.00 | -- | -- | -- | 5.70 | -- | 0.00 | -- |
| Atreca Inc | 0.00 | -97.76m | 3.65m | 90.00 | -- | 0.3388 | -- | -- | -2.49 | -2.49 | 0.00 | 0.2715 | 0.00 | -- | -- | 0.00 | -98.54 | -44.99 | -116.19 | -48.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 11.13 | -- | -8.46 | -- |
| Sonoma Pharmaceuticals Inc | 12.31m | -5.08m | 3.68m | 9.00 | -- | 0.4826 | -- | 0.2992 | -0.9608 | -0.9608 | 1.95 | 0.489 | 0.8625 | 2.58 | 4.76 | 1,367,778.00 | -35.56 | -37.52 | -47.14 | -51.35 | 39.17 | 40.17 | -41.23 | -37.12 | 3.11 | -- | 0.0065 | -- | 5.10 | -4.44 | -1.28 | -- | 7.54 | -- |
| Scorpius Holdings Inc | 2.23m | -46.05m | 3.73m | 77.00 | -- | 0.0744 | -- | 1.67 | -1.78 | -2.00 | 0.0859 | 1.39 | 0.0234 | -- | 0.6762 | 28,918.57 | -50.05 | -38.42 | -61.25 | -42.06 | 29.10 | -- | -2,136.28 | -703.02 | -- | -- | 0.2305 | -- | 202.12 | 33.24 | -23.85 | -- | 218.50 | -- |
| Eiger Biopharmaceuticals Inc | 15.77m | -74.96m | 3.78m | 25.00 | -- | -- | -- | 0.2396 | -50.80 | -50.80 | 10.69 | -9.77 | 0.1985 | 0.0064 | 9.19 | 630,920.00 | -94.31 | -60.25 | -186.10 | -76.51 | 99.91 | -- | -475.26 | -823.59 | 0.6809 | -22.03 | 1.54 | -- | 16.98 | -- | 22.54 | -- | 10.51 | -- |
| TRACON Pharmaceuticals Inc | 12.05m | -3.59m | 3.83m | 17.00 | -- | -- | -- | 0.3181 | -5.20 | -5.20 | 7.36 | -0.3655 | 0.8146 | -- | -- | 708,529.40 | -24.26 | -79.42 | -- | -177.85 | -- | -- | -29.79 | -813.81 | -- | -0.9444 | -- | -- | -- | 32.05 | 87.68 | -- | -- | -- |
| GB Sciences Inc | 0.00 | -4.03m | 3.86m | 3.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0119 | 0.00 | -- | -- | 0.00 | -255.86 | -49.16 | -- | -131.40 | -- | 6.03 | -- | -995.19 | -- | -8.63 | -- | -- | -- | -- | -2,715.25 | -- | -60.82 | -- |
| Clearmind Medicine Inc | 0.00 | -8.09m | 3.87m | -- | -- | 0.767 | -- | -- | -30.92 | -30.92 | 0.00 | 1.59 | 0.00 | -- | -- | -- | -109.55 | -218.20 | -180.61 | -488.96 | -- | -- | -- | -- | -- | -2.90 | 0.0184 | -- | -- | -- | -25.03 | -- | -- | -- |
| Mustang Bio Inc | 0.00 | -40.10m | 3.90m | 80.00 | -- | -- | -- | -- | -4.55 | -4.55 | 0.00 | -0.4757 | 0.00 | -- | -- | 0.00 | -90.93 | -70.02 | -138.05 | -79.98 | -- | -- | -- | -- | -- | -15.88 | -- | -- | -- | -- | 33.44 | -- | -60.75 | -- |
| Geovax Labs Inc | 0.00 | -25.97m | 3.92m | 17.00 | -- | 0.5832 | -- | -- | -14.25 | -14.25 | 0.00 | 2.91 | 0.00 | -- | -- | 0.00 | -127.82 | -108.34 | -160.47 | -147.24 | -- | -- | -- | -1,842.93 | -- | -- | 0.00 | -- | -100.00 | -- | -85.20 | -- | -- | -- |
Data as of May 17 2024. Currency figures normalised to Sonoma Pharmaceuticals Inc's reporting currency: US Dollar USD
2.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Citadel Securities LLCas of 31 Dec 2023 | 116.78k | 0.75% |
| G1 Execution Services LLCas of 31 Mar 2024 | 46.05k | 0.30% |
| Geode Capital Management LLCas of 31 Dec 2023 | 35.78k | 0.23% |
| Millennium Management LLCas of 31 Dec 2023 | 31.90k | 0.20% |
| HRT Financial LLCas of 31 Dec 2023 | 27.86k | 0.18% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 24.32k | 0.16% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2023 | 10.11k | 0.07% |
| Tower Research Capital LLCas of 31 Dec 2023 | 9.52k | 0.06% |
| UBS Securities LLCas of 31 Dec 2023 | 8.94k | 0.06% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.27k | 0.02% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
